

NEW BARD1 EXOSOME LIQUID BIOPSY PROJECT

- **Commercial Research Agreement signed with the Mucosal Immunology Research Group (MIRG) at Griffith University**
- **Aims to develop exosome-based RNA test for earlier detection of breast and ovarian cancer**
- **Leverages the Company's EXO-NET capture and BARD1 biomarker technologies**

Melbourne, Australia, 29 November 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) announces a new project to develop a BARD1 exosome liquid biopsy.

BARD1 has signed a Consultancy and Commercial Research Agreement with Griffith University to provide consultancy and scientific services to support the development and evaluation of an exosome-based BARD1 RNA test for detection of ovarian and breast cancers. The Agreement will be delivered through the experienced team at the Mucosal Immunology Research Group (MIRG) at Griffith University that has significant expertise in RNA analysis and profiling infection and inflammatory/immune responses. Plasma exosomes will be isolated using EXO-NET[®] at BARD1's US-based facility and then transferred to Griffith University for analysis using custom-built Nanostring[®] expression assays.

The project aims to develop exosome-based RNA tests for earlier detection of breast and ovarian cancers by combining the Company's EXO-NET exosome capture and BARD1 biomarker technologies.

CSO Dr Greg Rice said: "This project leverages the power of our EXO-NET technology to capture specific exosome populations and our BARD1 biomarker technology to enable the targeted profiling of exosomal RNAs thereby providing a more informative liquid biopsy for the presence of cancer."

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
CEO

E leearne@bard1.com

M +61 400 414 416

Dr Geoff Cumming

Non-executive Chairman

E geoff.cumming@bard1.com

M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is an Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com and www.exo-net.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.